Sign in
4

Changes in Ownership

BIOCRYST PHARMACEUTICALS INC Filed Acc 0001127602-19-018347

Senior Vice President and CFO sold 19,500 shares at an average $7.70 ($150,053)

  • Senior Vice President and CFO acquired 19,500 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
STAAB THOMAS R II Senior Vice President and CFO 2019-05-09 Option exercise +9,750 $5.51 $53,723 142,426 D: show line 1 in the form
STAAB THOMAS R II Senior Vice President and CFO 2019-05-09 Sale −9,750 $7.63 $74,393 132,676 D: show line 2 in the form
STAAB THOMAS R II Senior Vice President and CFO 2019-05-13 Option exercise +9,750 $5.51 $53,723 142,426 D: show line 3 in the form
STAAB THOMAS R II Senior Vice President and CFO 2019-05-13 Sale −9,750 $7.76 $75,660 132,676 D: show line 4 in the form
Open-market sales · 19,500 sh · avg $7.70 · $150,053

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
STAAB THOMAS R II Senior Vice President and CFO 2019-05-09 Option exercise · Emp. Stock Option (Right to Buy) −9,750 141,000 D: show line 5 in the form
STAAB THOMAS R II Senior Vice President and CFO 2019-05-13 Option exercise · Emp. Stock Option (Right to Buy) −9,750 131,250 D: show line 6 in the form
Loading xslF345X03/form4.xml…